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Figure 1.  Cascade of 
phosphorylation activities in the 
KRAS cell transduction pathway 






(Malumbres & Barbacid, 2003)
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Fig. 2 Complete coding 















Fig. 3 Complete coding 
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Fig. 5 Diagram of two-part 
SOE-PCR proces 
TA ligation 
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Fig. 6 Map of the pTarget 
overexpression vector
Transformation
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Fig. 7 Plate of E.coli  
transformed with KRAS R164L 
inserted in pTarget verified 
through Blue-white Screening
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Fig. 8 Results of Restriction Enzyme digestion showing positive 
insert of KRAS R164L in the pTarget vector
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Fig. 9 Chromatogram of 
sequencing results 
Fig. 9 Chromatogram of sequencing results 
Fig. 10 Sequence 
alignment through 
NCBI BLAST with 
interpretations

Fig. 11 Sequence 
alignment through 
NCBI BLAST with 
interpretations for 
variant b
Fig. 12 Protein sequence alignment through NCBI Blastx with 
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